J. Malcolm

Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance

C. Bult, J. Blake, D. Hill, 2019, BMC Cancer.

Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX)

C. Bult, J. Graber, S. Airhart, 2019, PeerJ.

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

S. Kobayashi, D. Costa, H. Reddi, 2017, Lung cancer.

Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.

Karen E. Rasmussen, C. Bult, G. Ananda, 2015, Experimental and molecular pathology.

Abstract 3630: Validation of the Archer FusionPlex solid tumor panel in the JAX cancer treatment profileTM

G. Ananda, C. Statz, S. Mockus, 2016 .

Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.

Karen E. Rasmussen, C. Bult, G. Ananda, 2015, Experimental and molecular pathology.